Mediastinal Masse or Heart base tumour in french bouledogue 🐕 скачать в хорошем качестве

Mediastinal Masse or Heart base tumour in french bouledogue 🐕

#cardiology #veterinary #echocardiography #cardiologie Chez le chien, la majorité (environ 80 %) des tumeurs cardiaques sont primitives (contrairement à l'homme, chez lequel les tumeurs cardiaques sont majoritairement métastatiques). À la différence de l'homme également, ces tumeurs primitives sont malignes dans 80 % des cas, car l'hémangiosarcome représente, de loin, la tumeur la plus fréquemment diagnostiquée. On distingue ainsi dans l'espèce canine, par ordre décroissant de malignité et de fréquence d'apparition, les tumeurs cardiaques primitives suivantes : hémangiosarcomes, chémodectomes et myxomes (bien plus rares). S'y ajoute une tumeur péricardique, le mésothéliome. n general, dogs with a heart base tumor have much longer median survival time than those with an RA mass (historically, ∼5 months vs less than 1 week, respectively). One study of dogs with a heart base mass found that successful pericardiectomy improved median survival time to about 2 years, compared to dogs with no surgery, where median survival was just over 1 month (Ehrhart, 2002). While many cardiac tumors are unresponsive to conventional therapies, some are treated with short-term success. Stereotaxic radiation therapy combined with elective pericardial window resulted in a median survival of about 400 days in a study of 28 dogs with chemodectoma; most dogs had at least partial response, with low rate of adverse radiation effects (Kruckman-Gatesy, 2020). Caval obstruction, regional lymph node enlargement, tachyarrhythmias, and clinical signs were negatively associated with survival in that study. In a retrospective study of toceranib (Palladia®), 27 dogs with heart base tumors had an overall median survival time of 823 days, with a wide range of survival (Lew, 2019). This study indicates that dogs affected by this tumor can have prolonged survival. Nevertheless, the retrospective nature of that study and the need for stringent disease staging and treatment blinding demands prospective assessment of toceranib for treating these neoplasms. Until that is available, an oncologist should be consulted regarding treatment options for chemodectoma. Because chemodectoma often is an incidental finding, clinical status and tumor staging at the time of diagnosis are considerations when assessing potential survival times. Management of canine HSA is less successful, in part because of Bibliographie : 👉Lew FH, McQuown B, Borrego J, Cunningham S, Burgess KE. Retrospective evaluation of canine heart base tumours treated with toceranib phosphate (Palladia): 2011-2018. Vet Comp Oncol. 2019 Dec;17(4):465-471. doi: 10.1111/vco.12491. Epub 2019 Jun 18. PMID: 31069932. 👉Treggiari E, Pedro B, Dukes-McEwan J, Gelzer AR, Blackwood L. A descriptive review of cardiac tumours in dogs and cats. Vet Comp Oncol. 2017 Jun;15(2):273-288. doi: 10.1111/vco.12167. Epub 2015 Sep 30. PMID: 26420436.